What is Biomarin Pharmaceutical Inc's earnings per share (EPS)?

Biomarin Pharmaceutical Inc (BMRN) reported diluted earnings per share of $1.80 for fiscal year 2025. This represents a -18.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Biomarin Pharmaceutical Inc Financials

BMRN

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Biomarin Pharmaceutical Inc (BMRN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 68/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Biomarin Pharmaceutical Inc has an operating margin of 12.7%, meaning the company retains $13 of operating profit per $100 of revenue. This results in a moderate score of 50/100, indicating healthy but not exceptional operating efficiency. This is down from 17.0% the prior year.

Growth

Biomarin Pharmaceutical Inc's revenue grew 12.9% year-over-year to $3.2B, a solid pace of expansion. This earns a growth score of 55/100.

Leverage

Biomarin Pharmaceutical Inc carries a low D/E ratio of 0.25, meaning only $0.25 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 5.21, Biomarin Pharmaceutical Inc holds $5.21 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

Biomarin Pharmaceutical Inc converts 22.5% of revenue into free cash flow ($725.0M). This strong cash generation earns a score of 81/100.

Returns

Biomarin Pharmaceutical Inc generates a 5.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 24/100. This is down from 7.5% the prior year.

Altman Z-Score Safe

5.39

Biomarin Pharmaceutical Inc scores 5.39, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($10.7B) relative to total liabilities ($1.5B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

4/9

Biomarin Pharmaceutical Inc passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

2.37x

For every $1 of reported earnings, Biomarin Pharmaceutical Inc generates $2.37 in operating cash flow ($828.0M OCF vs $348.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

37.6x

Biomarin Pharmaceutical Inc earns $37.6 in operating income for every $1 of interest expense ($409.5M vs $10.9M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$3.2B

YoY+12.9%

5Y CAGR+11.6%

10Y CAGR+13.7%

Biomarin Pharmaceutical Inc generated $3.2B in revenue in fiscal year 2025. This represents an increase of 12.9% from the prior year.

EBITDA

$489.0M

YoY-15.8%

5Y CAGR+51.3%

Biomarin Pharmaceutical Inc's EBITDA was $489.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 15.8% from the prior year.

Net Income

$348.9M

YoY-18.3%

5Y CAGR-16.4%

Biomarin Pharmaceutical Inc reported $348.9M in net income in fiscal year 2025. This represents a decrease of 18.3% from the prior year.

EPS (Diluted)

$1.80

YoY-18.6%

5Y CAGR-16.7%

Biomarin Pharmaceutical Inc earned $1.80 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 18.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$725.0M

YoY+48.7%

Biomarin Pharmaceutical Inc generated $725.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 48.7% from the prior year.

Cash & Debt

$1.3B

YoY+39.1%

5Y CAGR+15.1%

10Y CAGR+12.7%

Biomarin Pharmaceutical Inc held $1.3B in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

192M

YoY+0.8%

5Y CAGR+1.1%

10Y CAGR+1.8%

Biomarin Pharmaceutical Inc had 192M shares outstanding in fiscal year 2025. This represents an increase of 0.8% from the prior year.

Margins & Returns

Gross Margin

77.7%

YoY-1.9pp

5Y CAGR+5.9pp

10Y CAGR-5.2pp

Biomarin Pharmaceutical Inc's gross margin was 77.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.9 percentage points from the prior year.

Operating Margin

12.7%

YoY-4.3pp

5Y CAGR+15.0pp

10Y CAGR+25.1pp

Biomarin Pharmaceutical Inc's operating margin was 12.7% in fiscal year 2025, reflecting core business profitability. This is down 4.3 percentage points from the prior year.

Net Margin

10.8%

YoY-4.1pp

5Y CAGR-35.1pp

10Y CAGR+30.1pp

Biomarin Pharmaceutical Inc's net profit margin was 10.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 4.1 percentage points from the prior year.

Return on Equity

5.7%

YoY-1.8pp

5Y CAGR-15.1pp

10Y CAGR+12.9pp

Biomarin Pharmaceutical Inc's ROE was 5.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 1.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$921.9M

YoY+23.4%

5Y CAGR+8.0%

10Y CAGR+3.8%

Biomarin Pharmaceutical Inc invested $921.9M in research and development in fiscal year 2025. This represents an increase of 23.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$103.0M

YoY+20.6%

5Y CAGR-2.1%

10Y CAGR-7.6%

Biomarin Pharmaceutical Inc invested $103.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 20.6% from the prior year.

BMRN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$3.2B+12.9%	$2.9B+18.0%	$2.4B+15.4%	$2.1B+13.5%	$1.8B-0.8%	$1.9B
Cost of Revenue	$717.4M+23.6%	$580.2M+9.1%	$532.1M+5.8%	$503.0M+6.9%	$470.5M-10.3%	$524.3M
Gross Profit	$2.5B+10.1%	$2.3B+20.5%	$1.9B+18.5%	$1.6B+15.8%	$1.4B+3.0%	$1.3B
R&D Expenses	$921.9M+23.4%	$747.2M+0.1%	$746.8M+15.0%	$649.6M+3.3%	$628.8M+0.1%	$628.1M
SG&A Expenses	$1.2B+14.3%	$1.0B+13.1%	$892.4M+8.4%	$823.2M+8.4%	$759.4M+2.9%	$737.7M
Operating Income	$409.5M-15.4%	$484.2M+160.6%	$185.8M+15.4%	$161.0M+295.5%	-$82.3M-89.6%	-$43.4M
Interest Expense	$10.9M-14.0%	$12.7M-26.9%	$17.3M+8.5%	$16.0M+4.1%	$15.3M-47.7%	$29.3M
Income Tax	$133.6M+16.3%	$114.9M+449.3%	$20.9M+161.0%	$8.0M+171.1%	-$11.3M+98.8%	-$903.0M
Net Income	$348.9M-18.3%	$426.9M+154.6%	$167.6M+18.4%	$141.6M+320.9%	-$64.1M-107.5%	$854.0M
EPS (Diluted)	$1.80-18.6%	$2.21+154.0%	$0.87+16.0%	$0.75+314.3%	$-0.35-107.8%	$4.50

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$874.6M+12.7%	$776.1M-6.0%	$825.4M+10.8%	$745.1M-0.3%	$747.3M+0.2%	$745.7M+4.7%	$712.0M+9.7%	$648.8M
Cost of Revenue	$275.7M+96.8%	$140.1M-6.7%	$150.1M-1.0%	$151.6M+11.3%	$136.1M-27.8%	$188.5M+44.5%	$130.5M+4.2%	$125.2M
Gross Profit	$598.9M-5.8%	$636.0M-5.8%	$675.3M+13.8%	$593.6M-2.9%	$611.2M+9.7%	$557.3M-4.2%	$581.6M+11.1%	$523.7M
R&D Expenses	$192.4M-53.0%	$409.5M+153.8%	$161.3M+1.6%	$158.7M-8.5%	$173.5M-6.2%	$184.9M+0.6%	$183.8M-10.3%	$205.0M
SG&A Expenses	$446.2M+66.2%	$268.4M+15.6%	$232.3M+12.7%	$206.1M-22.7%	$266.6M+5.2%	$253.5M-3.6%	$263.0M+16.4%	$225.9M
Operating Income	-$44.6M+4.5%	-$46.7M-116.9%	$276.9M+23.7%	$223.9M+38.7%	$161.4M+41.7%	$113.9M-5.4%	$120.5M+36.2%	$88.5M
Interest Expense	$2.8M+7.7%	$2.6M-3.7%	$2.7M-6.4%	$2.9M+11.1%	$2.6M-13.2%	$3.0M-17.0%	$3.6M+0.8%	$3.5M
Income Tax	$19.4M+339.4%	$4.4M-92.3%	$57.3M+9.4%	$52.4M+17.2%	$44.7M+57.6%	$28.4M+13.6%	$25.0M+47.8%	$16.9M
Net Income	-$46.6M-51.5%	-$30.7M-112.8%	$240.5M+29.5%	$185.7M+48.6%	$124.9M+17.8%	$106.1M-1.0%	$107.2M+20.9%	$88.7M
EPS (Diluted)	N/A	$-0.16-113.0%	$1.23+29.5%	$0.95	N/A	$0.550.0%	$0.55+19.6%	$0.46

BMRN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$7.6B+8.7%	$7.0B+2.2%	$6.8B+7.3%	$6.4B+6.2%	$6.0B+2.7%	$5.8B
Current Assets	$4.0B+22.3%	$3.2B+9.3%	$3.0B+7.4%	$2.8B+21.0%	$2.3B-2.9%	$2.3B
Cash & Equivalents	$1.3B+39.1%	$942.8M+24.9%	$755.1M+4.2%	$724.5M+23.4%	$587.3M-9.5%	$649.2M
Inventory	$1.3B+5.4%	$1.2B+11.3%	$1.1B+23.8%	$894.1M+15.1%	$776.7M+11.2%	$698.5M
Accounts Receivable	$908.2M+37.5%	$660.5M+4.2%	$633.7M+37.4%	$461.3M+23.5%	$373.4M-16.7%	$448.4M
Goodwill	$196.2M0.0%	$196.2M0.0%	$196.2M0.0%	$196.2M0.0%	$196.2M0.0%	$196.2M
Total Liabilities	$1.5B+13.2%	$1.3B-29.6%	$1.9B+6.7%	$1.8B+1.9%	$1.7B-0.2%	$1.7B
Current Liabilities	$759.0M+25.0%	$607.0M-48.4%	$1.2B+99.9%	$588.9M+7.8%	$546.5M+11.0%	$492.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.1B+7.6%	$5.7B+14.3%	$5.0B+7.6%	$4.6B+7.9%	$4.3B+4.0%	$4.1B
Retained Earnings	$154.2M+179.2%	-$194.7M+68.7%	-$621.6M+21.2%	-$789.2M+15.2%	-$930.8M-8.0%	-$861.6M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$7.6B-0.3%	$7.6B+2.1%	$7.5B+4.3%	$7.1B+2.3%	$7.0B+2.0%	$6.9B-3.1%	$7.1B+2.8%	$6.9B
Current Assets	$4.0B+2.6%	$3.9B+1.3%	$3.8B+9.7%	$3.5B+7.3%	$3.2B+5.8%	$3.1B-6.2%	$3.3B+9.2%	$3.0B
Cash & Equivalents	$1.3B+4.9%	$1.3B+3.0%	$1.2B+15.7%	$1.0B+11.2%	$942.8M+39.6%	$675.4M-30.5%	$972.1M+30.1%	$747.0M
Inventory	$1.3B-6.0%	$1.4B+3.1%	$1.3B+5.1%	$1.3B+3.4%	$1.2B+4.5%	$1.2B-0.4%	$1.2B+4.0%	$1.1B
Accounts Receivable	$908.2M+14.9%	$790.3M-7.7%	$855.9M+15.8%	$739.2M+11.9%	$660.5M-15.0%	$777.5M+12.5%	$691.2M+8.5%	$637.2M
Goodwill	$196.2M0.0%	$196.2M0.0%	$196.2M0.0%	$196.2M0.0%	$196.2M0.0%	$196.2M0.0%	$196.2M0.0%	$196.2M
Total Liabilities	$1.5B-3.3%	$1.6B+9.0%	$1.4B+5.6%	$1.4B+1.7%	$1.3B-7.4%	$1.4B-19.3%	$1.8B-1.0%	$1.8B
Current Liabilities	$759.0M-4.9%	$798.4M+16.7%	$684.2M+8.9%	$628.2M+3.5%	$607.0M-15.2%	$715.7M-32.9%	$1.1B-1.9%	$1.1B
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.1B+0.5%	$6.1B+0.5%	$6.0B+4.0%	$5.8B+2.4%	$5.7B+4.5%	$5.4B+2.4%	$5.3B+4.2%	$5.1B
Retained Earnings	$154.2M-23.2%	$200.8M-13.3%	$231.5M+2669.9%	-$9.0M+95.4%	-$194.7M+39.1%	-$319.6M+24.9%	-$425.7M+20.1%	-$532.9M

BMRN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$828.0M+44.5%	$572.8M+259.7%	$159.3M-9.5%	$175.9M-42.2%	$304.5M+256.7%	$85.4M
Capital Expenditures	$103.0M+20.6%	$85.4M-11.7%	$96.7M-20.1%	$121.0M+26.6%	$95.6M-16.4%	$114.3M
Free Cash Flow	$725.0M+48.7%	$487.4M+679.0%	$62.6M+13.9%	$54.9M-73.7%	$209.0M+821.9%	-$28.9M
Investing Cash Flow	-$414.2M-403.5%	$136.5M+222.7%	-$111.2M-455.4%	-$20.0M+94.5%	-$366.3M-583.2%	-$53.6M
Financing Cash Flow	-$42.4M+91.9%	-$526.4M-2711.2%	-$18.7M-0.4%	-$18.6M-38754.2%	-$48K-100.0%	$181.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$0	$0-100.0%	$50.0M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$99.6M-73.0%	$368.7M+99.0%	$185.3M+6.2%	$174.4M-6.1%	$185.6M-16.2%	$221.5M+86.5%	$118.8M+152.8%	$47.0M
Capital Expenditures	$40.7M+43.2%	$28.4M+66.3%	$17.1M+2.0%	$16.8M-14.1%	$19.5M+5.8%	$18.5M-13.4%	$21.3M-18.3%	$26.1M
Free Cash Flow	$58.9M-82.7%	$340.2M+102.3%	$168.2M+6.7%	$157.6M-5.1%	$166.1M-18.2%	$203.0M+108.4%	$97.4M+366.9%	$20.9M
Investing Cash Flow	-$42.4M+87.2%	-$331.0M-2528.4%	-$12.6M+55.4%	-$28.2M-137.0%	$76.4M+572.9%	-$16.2M-117.9%	$90.5M+735.6%	-$14.2M
Financing Cash Flow	$3.2M+245.6%	-$2.2M+52.9%	-$4.6M+88.1%	-$38.8M-1456.4%	$2.9M+100.6%	-$499.1M-4057.5%	$12.6M+129.5%	-$42.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BMRN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	77.7%-1.9pp	79.7%+1.7pp	78.0%+2.0pp	76.0%+1.5pp	74.5%+2.7pp	71.8%
Operating Margin	12.7%-4.3pp	17.0%+9.3pp	7.7%0.0pp	7.7%+12.1pp	-4.5%-2.1pp	-2.3%
Net Margin	10.8%-4.1pp	15.0%+8.0pp	6.9%+0.2pp	6.8%+10.2pp	-3.5%-49.4pp	45.9%
Return on Equity	5.7%-1.8pp	7.5%+4.1pp	3.4%+0.3pp	3.1%+4.6pp	-1.5%-22.3pp	20.8%
Return on Assets	4.6%-1.5pp	6.1%+3.7pp	2.5%+0.2pp	2.2%+3.3pp	-1.1%-15.7pp	14.6%
Current Ratio	5.21-0.1	5.33+2.8	2.51-2.2	4.67+0.5	4.16-0.6	4.76
Debt-to-Equity	0.25+0.0	0.24-0.1	0.380.0	0.38-0.0	0.41-0.0	0.42
FCF Margin	22.5%+5.4pp	17.1%+14.5pp	2.6%-0.0pp	2.6%-8.7pp	11.3%+12.9pp	-1.6%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	68.5%-13.5pp	82.0%+0.1pp	81.8%+2.2pp	79.7%-2.1pp	81.8%+7.1pp	74.7%-7.0pp	81.7%+1.0pp	80.7%
Operating Margin	-5.1%+0.9pp	-6.0%-39.6pp	33.6%+3.5pp	30.0%+8.4pp	21.6%+6.3pp	15.3%-1.6pp	16.9%+3.3pp	13.6%
Net Margin	-5.3%-1.4pp	-4.0%-33.1pp	29.1%+4.2pp	24.9%+8.2pp	16.7%+2.5pp	14.2%-0.8pp	15.0%+1.4pp	13.7%
Return on Equity	-0.8%-0.3pp	-0.5%-4.5pp	4.0%+0.8pp	3.2%+1.0pp	2.2%+0.3pp	2.0%-0.1pp	2.0%+0.3pp	1.8%
Return on Assets	-0.6%-0.2pp	-0.4%-3.6pp	3.2%+0.6pp	2.6%+0.8pp	1.8%+0.2pp	1.6%+0.0pp	1.5%+0.2pp	1.3%
Current Ratio	5.21+0.4	4.83-0.7	5.56+0.0	5.52+0.2	5.33+1.1	4.27+1.2	3.05+0.3	2.74
Debt-to-Equity	0.250.0	0.26+0.0	0.240.0	0.230.0	0.24-0.0	0.27-0.1	0.34-0.0	0.35
FCF Margin	6.7%-37.1pp	43.8%+23.5pp	20.4%-0.8pp	21.1%-1.1pp	22.2%-5.0pp	27.2%+13.5pp	13.7%+10.5pp	3.2%

Similar Companies

Ionis Pharmaceuticals IONS

$12.4B

Bridgebio Pharma BBIO

$14.2B

Exelixis Inc EXEL

$11.4B

Ascendis Pharma ASND

$14.1B

Summit Therapeutics Inc SMMT

$15.0B

Frequently Asked Questions

What is Biomarin Pharmaceutical Inc's annual revenue?

Biomarin Pharmaceutical Inc (BMRN) reported $3.2B in total revenue for fiscal year 2025. This represents a 12.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Biomarin Pharmaceutical Inc's revenue growing?

Biomarin Pharmaceutical Inc (BMRN) revenue grew by 12.9% year-over-year, from $2.9B to $3.2B in fiscal year 2025.

Is Biomarin Pharmaceutical Inc profitable?

Yes, Biomarin Pharmaceutical Inc (BMRN) reported a net income of $348.9M in fiscal year 2025, with a net profit margin of 10.8%.

What is Biomarin Pharmaceutical Inc's EBITDA?

Biomarin Pharmaceutical Inc (BMRN) had EBITDA of $489.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Biomarin Pharmaceutical Inc's gross margin?

Biomarin Pharmaceutical Inc (BMRN) had a gross margin of 77.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Biomarin Pharmaceutical Inc's operating margin?

Biomarin Pharmaceutical Inc (BMRN) had an operating margin of 12.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Biomarin Pharmaceutical Inc's net profit margin?

Biomarin Pharmaceutical Inc (BMRN) had a net profit margin of 10.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Biomarin Pharmaceutical Inc's return on equity (ROE)?

Biomarin Pharmaceutical Inc (BMRN) has a return on equity of 5.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Biomarin Pharmaceutical Inc's free cash flow?

Biomarin Pharmaceutical Inc (BMRN) generated $725.0M in free cash flow during fiscal year 2025. This represents a 48.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Biomarin Pharmaceutical Inc's operating cash flow?

Biomarin Pharmaceutical Inc (BMRN) generated $828.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Biomarin Pharmaceutical Inc's total assets?

Biomarin Pharmaceutical Inc (BMRN) had $7.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Biomarin Pharmaceutical Inc's capital expenditures?

Biomarin Pharmaceutical Inc (BMRN) invested $103.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Biomarin Pharmaceutical Inc spend on research and development?

Biomarin Pharmaceutical Inc (BMRN) invested $921.9M in research and development during fiscal year 2025.

How many shares does Biomarin Pharmaceutical Inc have outstanding?

Biomarin Pharmaceutical Inc (BMRN) had 192M shares outstanding as of fiscal year 2025.

What is Biomarin Pharmaceutical Inc's current ratio?

Biomarin Pharmaceutical Inc (BMRN) had a current ratio of 5.21 as of fiscal year 2025, which is generally considered healthy.

What is Biomarin Pharmaceutical Inc's debt-to-equity ratio?

Biomarin Pharmaceutical Inc (BMRN) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Biomarin Pharmaceutical Inc's return on assets (ROA)?

Biomarin Pharmaceutical Inc (BMRN) had a return on assets of 4.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Biomarin Pharmaceutical Inc's Altman Z-Score?

Biomarin Pharmaceutical Inc (BMRN) has an Altman Z-Score of 5.39, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Biomarin Pharmaceutical Inc's Piotroski F-Score?

Biomarin Pharmaceutical Inc (BMRN) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Biomarin Pharmaceutical Inc's earnings high quality?

Biomarin Pharmaceutical Inc (BMRN) has an earnings quality ratio of 2.37x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Biomarin Pharmaceutical Inc cover its interest payments?

Biomarin Pharmaceutical Inc (BMRN) has an interest coverage ratio of 37.6x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Biomarin Pharmaceutical Inc?

Biomarin Pharmaceutical Inc (BMRN) scores 68 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.